Author

F. Larbret

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1

Frequent Co-Authors

C. Girard· 2 shared I. Berestjuk· 2 shared M. Deckert· 2 shared M. Lecacheur· 2 shared S. Diazzi· 2 shared S. Tartare-Deckert· 2 shared A. Baeri· 1 shared A. Carminati· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Girard

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Nanoblades allow high-level genome editing in organoids

V. Tiroille, A. Krug, E. Bokobza, M. Bulcaen, M. Ensinck, M. Geurts, D. Hendriks, F. Vermeulen, F. Larbret, A. gutierrez-Guerrero, M. Louise, R. Gijsbers, P. E. Mangeot, H. Clevers, M. Carlon, , E. Verhoeyen

This paper introduces nanoblade technology for efficient, low-toxicity genome editing in organoids, achieving up to 80% gene knockout in murine and human organoids.

bioRxiv · Aug 4, 2022 · PreprintBioengineering

Blockade of pro-fibrotic response mediated by the miR-143/-145 cluster prevents targeted therapy-induced phenotypic plasticity and resistance in melanoma

S. Diazzi, A. Baeri, J. Fassy, M. Lecacheur, O. Marin-Bejar, C. Girard, L. Lefevre, C. Lacoux, M. Irondelle, C. Mounier, M. Truchi, M. Couralet, A. Carminati, I. Berestjuk, F. Larbret, , S. Tartare-Deckert

This study identifies the miR-143/-145 cluster as a driver of therapy-resistant mesenchymal-like phenotype in melanoma and shows that blocking its pro-fibrotic effects enhances MAPK inhibitor efficacy.

bioRxiv · Jul 2, 2021Cancer Biology

Targeting DDR1 and DDR2 overcomes matrix-mediated melanoma cell adaptation to BRAF-targeted therapy

S. Tartare-Deckert, I. Berestjuk, M. Lecacheur, S. Diazzi, C. Rovera, V. Prod'homme, A. Mallavialle, F. Larbret, S. Pisano, S. Audebert, T. Passeron, C. Gaggioli, C. Girard, M. Deckert

This study shows that targeting DDR1 and DDR2 overcomes matrix-mediated resistance to BRAF inhibitors in melanoma by disrupting ECM-driven survival pathways.

bioRxiv · Nov 28, 2019 · PreprintCancer Biology